Abbvie Inc ABBV

$288.96 -5.93 (-2.01%)

Valuation

Market cap
521,009,600,000
Revenue TTM
$61,160,000,000
Net income TTM
$4,226,000,000
P/E (trailing)
26.75
P/E (forward)
20.89
Profit margin
6.91%
Debt to equity
-12.03

Trading

Volume
4,863,999
Avg volume
4,609,686
Day's range
$286.14 – $294.86
Shares out
1,766,793,000
Stochastic %K
81%
Beta
0.24
Analysts
Moderate Buy
Price target
$283.87

Price

Company profile

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to...

Show more

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox Cosmetic for the treatment of glabellar lines, crow's feet, forehead lines, and platysma bands; Juvederm Collection to treat volume loss in the temples, undereye, cheeks, chin, lips and lower face; Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder; Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; Qulipta for episodic and chronic migraine; and Vyalev for the treatment of motor fluctuations, as well as Botox Therapeutic to treat chronic migraine, overactive bladder, spasticity, cervical dystonia, and other conditions. In addition, the company offers Ozurdex for visual impairment; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; and other eye care products, including Refresh/Optive, Xen, Durysta, and Restasis. Further, it provides Mavyret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; and Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Industry
Drug Manufacturers - General
Sector
Healthcare
Phone
847 932 7900
Website
https://www.abbvie.com
Address
1 North Waukegan Road, North Chicago, United States

Latest news

Stocktwits

Benny_Cellura Nov 2, 6:54 PM
$CLS $RCAT $TXN $ABBV $CJMB ******
0 replies
VerifiedSqueeze Nov 2, 6:48 PM
Massive run starting on BTOC now! Let's see a massive squeeze on BTOC next! Same whales that sent CLRO for 300% are on BTOC now! $ABVEW $ABBV $ABA $SLS Watching
0 replies
55X_ROI_Q1_2026 Nov 2, 6:37 PM
$SLS VIALE-M -- Onureg (Oral Az ) + Venetoclax $ABBV Massive Phase 3 trial for AML remission Patients - Mostly CR1, but some CR2 were enrolled - VIALE M was a direct competitor to GPS AML Second Remission --- and it FAILED.... Direct Competitive AML Remissoin Trial with REGAL and it FAILED. VIALE-M - FAILED to Increase Survival above Standard of Care -- •••• adding Venetoclax to ORAL Az - FAILED. • VIALE-T - FAILED to Increase Survival • VERONA - FAILED to Increase Survival • OPTI-AML - FAILED to Increase Survival • Paradigm - FAILED to Increase Survival //
0 replies
55X_ROI_Q1_2026 Nov 2, 5:50 PM
$SLS Abbvie $ABBV tried 8 Different Dosing Schemes in the VIALE-M - AML First Remission Maintenance Trials Oral Aza + Oral Venetoclax with multiple doses SUBq/ IV / + Oral Az or Oral Ven --- THEY ALL FUCKING FAILED ... BAT FAILED the SLS REGAL CONTROL ARM PATIENTS TOO.
0 replies
55X_ROI_Q1_2026 Nov 2, 5:47 PM
$SLS Years ago... VIALE-M -- Onureg (Oral Az ) +Venetoclax - was the only thing, I was worried about -- $ABBV Massive Phase 3 trial for AML remission Patients - Mostly CR1, but some CR2 were enrolled --- and it FAILED.... Direct Competitive AML Remissoin Trial with REGAL and it FAILED. VIALE-M - FAILED to Increase Survival above Standard of Care -- adding Venetoclax to ORAL Az - FAILED. VIALE-T - FAILED to Increase Survival VERONA - FAILED to Increase Survival OPTI-AML - FAILED to Increase Survival Paradigm - FAILED to Increase Survival
0 replies
55X_ROI_Q1_2026 Nov 2, 5:43 PM
$SLS @Nasfact why do you think, the short n distort team/ campaign, fraudstein, seeking alpha, all the lowlife all over social media, are so AGGRESSIVE NOW -- instead of waiting for the share price to Rise and then short the results??? while p3 results are a couple weeks away... they they think they have a small window of time, to con and fleece ignorant retail, and other idiot inch thich retail shorts. 3 years ago, VIALE-M -- Onureg (Oral Az ) +Venetoclax - was the only thing, I was worried about -- $ABBV Massive Phase 3 trial for AML remission Patients - Mostly CR1, but some CR2 were enrolled --- VIALE-M FAILED to Increase Survival above Standard of Care -- VIALE-T FAILED to Increase Survival VERONA FAILED to Increase Survival OPTI-AML FAILED to Increase Survival Paradigm to Increase Survival
0 replies
biolover Nov 2, 4:37 PM
$VKTX Per $ABBV statement ABBV295 amylin phase 1 b data by year end .. chief MD believes will get better outcome as heavier population. I think he will be disappointed and will be wake up call to CEO who wants to seriously compete in obesity $PFE guided data by year end.. or next year ? Delayed a lot from last year expectation. I doubt to present data this week as may derail SP strength. Amylin based combination destined to failure. Time will show that.
1 replies
Oldpuck Nov 2, 4:05 PM
$ABBV I thought earnings were good
0 replies